Core Research Facilities

In This Section

GMP Facility

Cell Immunotherapy and Gene Therapy (CITGT) Good Manufacturing Practice (GMP) Facility

The Cell Immunotherapy and Gene Therapy GMP facility supports the manufacture of investigational new drug (IND) products for principal investigators under FDA rules and regulations.

The facility consists of 3,000 square feet and is located on the North Campus of Roger Williams Medical Center. The facility was established in 2001 to support the adoptive T-cell therapy program of immunotherapy and also serve as a core for the Roger Williams’ cancer center, surgical immunotherapy, gene therapy, and biotherapeutic development programs. Our specialized GMP facility is one of the eight facilities in nation that support adoptive T-cell therapy based phase I and phase II clinical trials that require gene modified T-cells or bispecific antibody conjugated T-cells.

GMP Facility: Features

GMP Facility: Equipments

(# = Equipment on real-time monitoring and alarm system)

GMP Facility: Services and Capabilities

For inquiries regarding clinical trials, research collaborations, and cell production, please contact:

Steven C. Katz, MD, FACS
Associate Professor of Surgery 
Boston University School of Medicine
Director, Complex Surgical Oncology Fellowship 
Director, Surgical Immunotherapy
Roger Williams Medical Center
825 Chalkstone Avenue, Prior 4, Providence, RI 02908
Appointments: 401-456-2077
Academic Office: 401-456-2484
Fax: 401-456-6708

Prajna Guha, PhD
Research Scientist/Production & Compliance Supervisor

Anthony Bais, PhD
Research Scientist/Biologic Product Development Supervisor